

Electronically filed on April 26, 2011

**Confirmation No. 6175
Customer No. 20462**

Attorney Docket No. PB60024USW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Irving, et al.

Serial No.:10/550,363

Group Art Unit No.: 1649

Filed: April 15, 2007

Examiner: Kolker, Daniel E.

For: Therapeutical Use of Anti-Myelin Associated Glycoprotein (Mag)
Antibodies

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

AMENDMENT & RESPONSE UNDER 37 C.F.R. §1.114(c)

In response to the Notice of Allowance mailed January 28, 2011 and the Office Communication mailed March 8, 2011, the Applicants respectfully request continued examination and consideration of this amendment and response to include an information disclosure statement and amendments to the specification. As this response is timely filed within the period for response of 3 months for the Notice of Allowance and within the shortened statutory period of 2 month for the March Office Communication, no extension of time fee is required. Please charge any additional requisite fees relating to this amendment and response to Deposit Account No. 19-2570.

Listing of the Claims begin on page 2 of this paper.

Amendments to the Specification begin on page 4 of this paper.

Remarks begin on page 5 of this paper.